Literature DB >> 33512778

Which is preferred for initial treatment of papillary thyroid cancer, total thyroidectomy or lobotomy?

Zhen Wu1, Lin Han2, Wenlei Li1, Wei Wang1, Liqaing Chen1, Yumin Yao1, Yongkun Wang1.   

Abstract

PURPOSES: The incidence of thyroid cancer has increased annually, and has a heavy psychological and economic burden on society and individuals. Based thyroid cancer data from patients treated in Liaocheng People's Hospital from 2015 to 2018, with Chinese national and regional characteristics, in this study, we addressed the controversy of which initial thyroid surgical mode, lobectomy or total thyroidectomy, is most effective.
METHODS: Clinical and pathological data from 2108 patients with thyroid cancer, who were initially diagnosed and treated surgically, were collected from the Department of Thyroid Surgery. Among them, there were 1001 cases who underwent open operation with total thyroidectomy + central lymph node dissection; meanwhile, 1107 cases were treated with neck lateral lymph node dissection at the same time.
RESULTS: The overall metastasis rate of all patients was 57.23%. Even the lymph node metastasis of papillary thyroid microcarcinoma (PTMC) was as high as 48.97%. When the mass rose above 2 cm, the proportion of metastasis increased to 77.22%. When the tumor was complicated with bilateral and multiple high-risk factors, the proportion of metastasis was 65.27% and 72.21%, respectively. When the tumor breaks through the capsule, the metastasis rate was 67.08%. With the increase of tumor diameter, the metastasis of cervical lymph nodes ranged from 22.54% to 73.33%, which showed positive correlation. 49.32% of patients had lymph node metastasis in the lateral cervical region. When the diameter of the tumor reached T1c level, the metastasis of the cervical lymph nodes was 56.91%, and the number of metastatic cases above T1c level accounted for 69.96% of the total metastatic cases.
CONCLUSION: The degree of malignancy of thyroid cancer depends on tumor genome evolution. Rates of neck lymph node metastasis are high, particularly among patients with risk factors for poor prognosis. It is recommended that initial treatment should comprise at least total thyroidectomy + central lymph node dissection in China, to avoid the risks associated with secondary surgery and effects on patient quality of life. When the tumor diameter exceeds 1 cm, the risk of cervical lymph node metastasis is high, and we recommended lateral lymph node dissection.
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Entities:  

Keywords:  initial treatment; metastasis; surgery; thyroid cancer

Mesh:

Year:  2021        PMID: 33512778      PMCID: PMC7940239          DOI: 10.1002/cam4.3743

Source DB:  PubMed          Journal:  Cancer Med        ISSN: 2045-7634            Impact factor:   4.452


  25 in total

1.  Korea's thyroid-cancer "epidemic"--screening and overdiagnosis.

Authors:  Hyeong Sik Ahn; Hyun Jung Kim; H Gilbert Welch
Journal:  N Engl J Med       Date:  2014-11-06       Impact factor: 91.245

Review 2.  Impact of enhanced detection on the increase in thyroid cancer incidence in the United States: review of incidence trends by socioeconomic status within the surveillance, epidemiology, and end results registry, 1980-2008.

Authors:  Nan Li; Xianglin L Du; Lorraine R Reitzel; Li Xu; Erich M Sturgis
Journal:  Thyroid       Date:  2013-01       Impact factor: 6.568

Review 3.  Low-risk papillary microcarcinoma of the thyroid: A review of active surveillance trials.

Authors:  Y Ito; A Miyauchi; H Oda
Journal:  Eur J Surg Oncol       Date:  2017-03-16       Impact factor: 4.424

Review 4.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

5.  Extent of surgery affects survival for papillary thyroid cancer.

Authors:  Karl Y Bilimoria; David J Bentrem; Clifford Y Ko; Andrew K Stewart; David P Winchester; Mark S Talamonti; Cord Sturgeon
Journal:  Ann Surg       Date:  2007-09       Impact factor: 12.969

Review 6.  An update on thyroid surgery.

Authors:  O Gimm; M Brauckhoff; P N Thanh; C Sekulla; H Dralle
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-07-11       Impact factor: 9.236

Review 7.  Unintentional recurrent laryngeal nerve injuries following thyroidectomy: Is it the surgeon who pays the bill?

Authors:  C Gambardella; A Polistena; A Sanguinetti; R Patrone; S Napolitano; D Esposito; D Testa; V Marotta; A Faggiano; P G Calò; N Avenia; G Conzo
Journal:  Int J Surg       Date:  2017-05       Impact factor: 6.071

8.  The occurrence of and predictive factors for multifocality and bilaterality in patients with papillary thyroid microcarcinoma.

Authors:  Krzysztof Kaliszewski; Dorota Diakowska; Beata Wojtczak; Jakub Migoń; Agata Kasprzyk; Jerzy Rudnicki
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

9.  Predicting factors of lateral neck lymph node metastases in patients with papillary thyroid microcarcinoma.

Authors:  Xin Wu; Binglu Li; Chaoji Zheng; Xiaodong He
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

Review 10.  Poorly differentiated thyroid carcinoma : An underdiagnosed entity.

Authors:  M S Dettmer; A Schmitt; P Komminoth; A Perren
Journal:  Pathologe       Date:  2020-06       Impact factor: 1.011

View more
  1 in total

1.  Risk-stratified papillary thyroid microcarcinoma: post-operative management and treatment outcome in a single center.

Authors:  Wasit Kanokwongnuwat; Noppadol Larbcharoensub; Chutintorn Sriphrapradang; Chaiyawat Suppasilp; Kanungnij Thamnirat; Chaninart Sakulpisuti; Arpakorn Kositwattanarerk; Chirawat Utamakul; Chanika Sritara; Wichana Chamroonrat
Journal:  Endocrine       Date:  2022-04-27       Impact factor: 3.925

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.